Combining orelabrutinib with R-CHOP for treating newly diagnosed double expression DLBCL

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter, prospective, single-arm phase II study aims to evaluate the safety and efficacy of orelabrutinib in combination with the R-CHOP regimen for treatment-naïve patients diagnosed with double expression diffuse large B-cell lymphoma (DLBCL). Patients will receive 6 to 8 cycles of treatment, with each cycle lasting 21 days. The primary objective is to assess the complete response rate at the end of the induction therapy. This study seeks to provide a new treatment option for patients with this aggressive form of lymphoma.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Newly diagnosed Double Expression Diffuse Large B-cell Lymphoma

  * Age 18-70 years
  * ECOG performance status 0-2
  * Ann Arbor stage II-IV
  * 8.Subjects who in line with the testing standard of the clinical trial laboratory
  * Life expectancy ≥ 3months

Exclusion Criteria:

* • systemic lymphoma involved CNS.

  * Accompanied by uncontrolled cardiovascular and cerebrovascular diseases, coagulopathy, connective tissue diseases.
  * uncontrolled infections (including HBV, HCV, HIV/AIDS)
  * Subjects who prepared for transplantation
  * Pregnancy or active lactation

Where it's running

• The First Ailliated Hospital of Nanchang University
  Nanchang, Jiangxi, China Recruiting
• Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences
  Jinan, Shandong, China Recruiting

Study contacts

• Study coordinator: zengjun Li
• Email: zengjunli@163.com
• Phone: 13642138692

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Orelabrutinib plus Pola-R-CHP as first-line treatment for intermediate- to high-risk DLBCL

  This trial tests whether adding orelabrutinib to the Pola-R-CHP regimen can improve outcomes for adults with intermediate- to high-risk newly diagnosed DLBCL.

  Recruiting at 2 sites The First Affiliated Hospital of Xiamen University · Xiamen, Fujian and 1 other locations · NCT07778212

• Orelabrutinib with Obinutuzumab and Short-Course Venetoclax in Treatment-Naïve Mantle Cell Lymphoma

  This trial tests whether a combo of orelabrutinib, obinutuzumab, and a short course of venetoclax is safe and effective for adults with newly diagnosed mantle cell lymphoma.

  Recruiting at 2 sites Phase 2 The First Affiliated Hospital with Nanjing Medical University · Changzhou, Jiangsu and 1 other locations · NCT07719556

• Orelabrutinib plus standard immunochemotherapy with or without auto-HSCT for newly diagnosed DLBCL

  This study tests whether adding orelabrutinib to standard chemotherapy, with or without autologous stem cell transplantation, helps newly diagnosed DLBCL patients.

  Recruiting Phase 2 The Affiliated Hospital of Xuzhou Medical University · Xuzhou, Jiangsu · NCT07680933

• High-dose dexamethasone plus orelabrutinib versus placebo for newly diagnosed adult ITP

  This trial tests whether adding orelabrutinib to high-dose dexamethasone helps adults newly diagnosed with primary ITP raise and maintain their platelet counts compared with placebo.

  Recruiting Phase 3 Shandong University · Jinan, Shandong · NCT07559331

• Ultra-low-dose radiation followed by orelabrutinib for early-stage MALT lymphoma

  This study will test whether a short course of very low-dose radiation followed by daily orelabrutinib helps adults with stage I–II MALT lymphoma keep their disease controlled with acceptable side effects.

  Recruiting at 2 sites Phase 2 Zhejiang Cancer Hospital · Hangzhou, Zhejiang and 1 other locations · NCT07554898

• Orelabrutinib for relapsed or refractory AIHA

  This study tests whether taking orelabrutinib by mouth can help adults with relapsed or refractory autoimmune hemolytic anemia (AIHA).

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT07453368

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.